Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. - Wikidata - awgldk - TriplyDB

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

http://www.wikidata.org/entity/Q37331117

about

New approaches for precise response evaluation in hepatocellular carcinoma Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging MR Imaging Biomarkers in Oncology Clinical Trials Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.Assessing Treatment Response Through Generalized Pharmacokinetic Modeling of DCE-MRI Data.[Quantitative perfusion imaging in magnetic resonance imaging].Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.Monitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI.Functional and molecular imaging with MRI: potential applications in paediatric radiology.Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Magnetic resonance in the era of molecular imaging of cancer Targeted therapies in renal cell cancer: recent developments in imaging Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.Molecular imaging in cancer treatment.Sunitinib and other targeted therapies for renal cell carcinoma.Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT.Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib.Imaging for assessment of treatment response in hepatocellular carcinoma: Current update.Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Gd-EOB-DTPA for the Evaluation of Liver Fibrosis Induced by Carbon Tetrachloride in Rats Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.MRI phenotype in renal cancer: is it clinically relevant?Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors Reproducibility of Dynamic Contrast-Enhanced MRI in Renal Cell Carcinoma: A Prospective Analysis on Intra- and Interobserver and Scan-Rescan Performance of Pharmacokinetic Parameters.Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma Assessment of esophageal carcinoma undergoing concurrent chemoradiotherapy with quantitative dynamic contrast-enhanced magnetic resonance imaging.Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging.Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings.Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments.Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.Sorafenib: where do we go from here?Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging in rectal cancer and its correlation with tumor differentiation.Evaluation of cancer treatment in the abdomen: Trends and advances.Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.

P2860

Q26866367-2805F880-014C-4818-8D63-66B7BA336AF5 Q27346895-E3D6C493-684B-497B-921C-C1356807279A Q30364608-11B95AA5-F20A-47C7-A034-5D40383382E9 Q30448049-68268548-C2A1-44B7-8821-8AFDC6B25E4E Q30806067-621191EA-BB8A-47DC-9A13-60E453BF5868 Q30990964-BE236ED4-801E-40CE-8BB8-DF0ABA34469D Q31038899-4A6F13E6-E853-4B47-8952-A916EE896BC1 Q31119452-5AA28548-E47C-4DEF-92E3-4065EC1AC2D4 Q32176092-A6F1B2DA-B434-4D9B-AA2C-D0D9C2245EDA Q33726910-FA2D77EC-16F1-430A-902A-B3471157DC11 Q33755947-F02A7E08-E86C-4A0B-B69E-153206F6CBDF Q33770680-D7CD4241-FC57-4CF2-B804-5DEF8B8F9C86 Q33883070-C7600DC5-9C88-4FE2-8A44-3E8B26298DB5 Q34088696-8D597217-9B48-418B-A0D6-69F5D9353860 Q34111200-D8469687-7396-4F4C-A2C5-A2A2CD89BDFB Q34496670-BD8389A6-FE86-4E99-A547-C09607345C01 Q34621802-DDB1F05F-428F-41C1-955D-A4DAC06827D4 Q34952709-B0D87496-141E-4F95-9B9C-D531F2BC6EEA Q35109141-09C75CBA-4DEA-4DBB-B513-73915AD82C49 Q35214229-2717EE13-897A-46FD-B21D-90BD127EB360 Q35568722-CE61F5F5-BFAE-4219-9352-5208B8F194BE Q35664034-D13031B9-D9D0-4BA0-98E4-1EF96125EAFB Q35697737-629A2934-046E-454A-9A7F-1E7A7F6C39E2 Q35793032-21F207B9-60AB-4A2F-A684-091EDCB87C01 Q35879814-91114AEA-9CE7-4492-A47A-4C4285D940D1 Q35915719-BEC95EAF-E0F3-470A-9D1C-8070417C95FE Q35918770-618C4DDC-86A4-4AA0-8176-2F4E28D972BA Q36256130-8AC653C2-990E-485C-B614-D916B6C8719E Q36279172-88CFA67F-3186-4EED-A6A3-27C091130498 Q36335500-70BE5BFB-63B3-4C0D-8FF9-D6DA983808FE Q36343788-B7198F8D-D547-4251-B580-EC9B0C37B472 Q36352484-507422AF-2BAD-4EB3-9932-CF2C1C86F6A5 Q36417718-BF671E0E-F6C1-40F6-8A9A-B867880256D2 Q36421776-5FFEFEE4-8E9F-4A07-A955-FCE716F2CA30 Q36567385-7FB880F2-3D59-4FA8-9B01-06C126843200 Q36708741-5FDEB699-1D3A-4CB4-A85B-6F80158944DE Q36741067-B7349E1C-97EB-4DBD-B742-11DB3CE423DA Q36832118-B5DFB4AA-9AC0-4031-B643-50EE951BC6C5 Q36864032-96348D59-716B-4C1F-8744-A03B44054F9C Q37085863-5200F893-C380-40D8-A62C-2D3910AC8EA8

P2860

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

http://www.wikidata.org/entity/Q37331117

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dynamic contrast-enhanced magn ...... in metastatic renal carcinoma.

@en

Dynamic contrast-enhanced magn ...... in metastatic renal carcinoma.

@nl

type

label

Dynamic contrast-enhanced magn ...... in metastatic renal carcinoma.

@en

Dynamic contrast-enhanced magn ...... in metastatic renal carcinoma.

@nl

prefLabel

Dynamic contrast-enhanced magn ...... in metastatic renal carcinoma.

@en

Dynamic contrast-enhanced magn ...... in metastatic renal carcinoma.

@nl

P1433

Q37331117-A3EB53A1-7C85-47D0-B846-B1BCB35BD27B

P1476

Q37331117-0A0DA30C-19BD-40CA-BDFA-9BC52A1E25F5

P2093

Q37331117-60F86F68-5EA1-4E73-8E9D-614BEA7BC7B3

Q37331117-67F4A014-3131-4685-B3A6-AB0CE9B0E22B

Q37331117-80EE7736-5F09-445C-A679-0CE3C71CED16

Q37331117-A2AF389A-AEEE-4322-81CD-3D013682FBF7

Q37331117-BEA114B3-A5BC-4E26-8F77-D7B1814DF58C

Q37331117-CB1D8843-253D-40BD-AD2D-9DCF1A98274B

Q37331117-E518E79D-FBA5-42BA-A46F-253D140F3F65

Q37331117-F3FAB506-BA01-48B5-9564-07CDA9A2099B

Q37331117-F9F75D49-D7CC-4395-83D2-2F60A3036365

P2860

Q37331117-12D26BD2-3B90-418F-B768-1E923DE88909

Q37331117-1643AC6B-F447-4296-AEE6-8C17EC24B3DE

Q37331117-1C54B836-5B3F-44AD-8830-1D3004FF68CA

Q37331117-1D619C90-A730-45C6-A611-7094F25B524F

Q37331117-1E7C97F2-5636-4DBE-8C5D-4E523704F5F2

Q37331117-3FE2423A-6894-4041-A635-D58AD739BA53

Q37331117-416ED69C-EB0C-44D0-A073-FDE78B9286D8

Q37331117-428F7A22-D1D5-492B-ABE0-E6E45B10CCD8

Q37331117-45F3A126-B62F-4AC2-9C89-D4E13CA46840

Q37331117-508EB46E-2BC5-474E-AE8B-B27873874759

P304

Q37331117-40B5A9D2-B16A-47FF-9A1A-09C006C2E7EA

P31

Q37331117-CE923616-2F0C-4E57-8E62-5D3883E6884C

P356

Q37331117-FFEF8AAE-672A-4D01-8CD8-BBE59E5AC60B

P407

Q37331117-B4E53C0B-AE63-4467-A9B8-271C4965551B

P433

Q37331117-8DC15AA2-2CC5-47FA-B3F9-116BBE70BB54

P478

Q37331117-B35FB563-3319-4539-9FBA-43F5B88B25DD

P50

Q37331117-7A91DAA4-173A-445D-9B9D-89CDADBDF903

P577

Q37331117-515A3523-750E-4109-9BA7-526BAE35ED04

P698

Q37331117-7F4D73F7-F1C8-4DB0-B94D-E109A8461A16

P921

Q37331117-127B90BC-3296-4A54-BF9F-53A902A96B05

P932

Q37331117-C8C56A13-3D75-4972-9B46-8974A90C5F8D

P356

JCO.2007.15.5655

P1433

Journal of Clinical Oncology

P1476

Dynamic contrast-enhanced magn ...... in metastatic renal carcinoma.

@en

P2093

Cheng Yang

http://www.w3.org/2001/XMLSchema#string

Elizabeth Manchen

http://www.w3.org/2001/XMLSchema#string

Emily Kistner

http://www.w3.org/2001/XMLSchema#string

Gregory Karczmar

http://www.w3.org/2001/XMLSchema#string

Milica Medved

http://www.w3.org/2001/XMLSchema#string

Myrosia Mitchell

http://www.w3.org/2001/XMLSchema#string

Olwen M Hahn

http://www.w3.org/2001/XMLSchema#string

Theodore Karrison

http://www.w3.org/2001/XMLSchema#string

Walter M Stadler

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents.

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

MRI of tumor angiogenesis.

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

P304

4572-4578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.15.5655

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18824708

http://www.w3.org/2001/XMLSchema#string

P921

P932

2736992

http://www.w3.org/2001/XMLSchema#string